eISSN: 1644-4124
ISSN: 1426-3912
Central European Journal of Immunology
Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
4/2011
vol. 36
 
Share:
Share:
abstract:

Clinical immunology
Early and late activation markers on thymus-dependent lymphocytes and natural killer cells in the blood of children with adenoid hypertrophy and concomitant otitis media with effusion

Andrzej Wojdas
,
Wanda Stankiewicz
,
Beata Zielnik-Jurkiewicz
,
Elżbieta Sobiczewska
,
Anna Stasiak-Barmuta

(Centr Eur J Immunol 2011; 36 (4): 262-266)
Online publish date: 2011/12/24
View full text Get citation
 
Adenoid hypertrophy is one of the reasons of otitis media with effusion. The aim of this study was to inquire whether it has got an influence on the number and activity of peripheral blood T and NK cells. The examined group consisted of 119 children with adenoid hypertrophy. The first group consisted of 44 children with only one episode of otitis media with effusion (OME). The second group consisted of 45 children with more than 4 episodes of OME and the third group consisted of 30 children with adenoid hypertrophy without OME. Evaluation of percentage of CD4+, CD8+ and NK subsets with co-expression of CD69, HLA-DR molecules in peripheral blood was performed by flow cytometry method. In examined groups with OME the decrease of CD4 number was compensated by increase of the number of NK and CD19 cells. In these groups the increase of CD69 and HLA-DR expression on the examined subsets was observed. The results suggest that recurrent otitis media with effusion may be one of the factors causing T lymphocytes deficiency. Obtained results might be one of the criteria of using adenoidectomy.
keywords:

otitis media with effusion, lymphocytes subsets, peripheral blood, flow cytometry

Quick links
© 2024 Termedia Sp. z o.o.
Developed by Bentus.